NASDAQ:SGTX

Sigilon Therapeutics Stock Forecast, Price & News

$2.20

+0.03 (+1.38%)

(As of 01/14/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.07
▼
$2.23
50-Day Range: $2.17
▼
$5.15
52-Week Range: $2.07
▼
$45.00

Volume: 97,721 shs
Average Volume: 109,480 shs
Market Capitalization: $71.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive SGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Sigilon Therapeutics

Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Sigilon Therapeutics Inc Shares Fall 4.4% Below Previous 52-Week Low - Market Mover
January 14, 2022 | nasdaq.com

Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Receives Consensus Rating of "Buy" from Analysts
January 12, 2022 | americanbankingnews.com

Sigilon Therapeutics (NASDAQ:SGTX) PT Lowered to $7.00
December 23, 2021 | americanbankingnews.com

Sigilon Therapeutics to lay off 40 employees
December 14, 2021 | finance.yahoo.com

The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
December 14, 2021 | markets.businessinsider.com

Sigilon Therapeutics Announces Strategic Reprioritization
December 13, 2021 | finance.yahoo.com

Shareholders in Sigilon Therapeutics (NASDAQ:SGTX) have lost 90%, as stock drops 15% this past week
December 8, 2021 | finance.yahoo.com

Sigilon Therapeutics, Inc. Common Stock (SGTX)
December 6, 2021 | nasdaq.com

Sigilon Therapeutics Issues An Update On Its Early-Stage Hemophilia Study
November 29, 2021 | benzinga.com

Sigilon Therapeutics Announces Update on SIG-001 Phase 1/2 Study in Hemophilia A
November 29, 2021 | finance.yahoo.com

Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
November 10, 2021 | finance.yahoo.com

Flagship Pioneering Launches Alltrna to Unlock Transfer RNA Biology and Treat Thousands of Diseases with a Single tRNA Medicine
November 9, 2021 | finance.yahoo.com

Sigilon Therapeutics to Participate in the Jefferies London Healthcare Conference
November 9, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: N/A
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SGTX
Previous Symbol
CUSIP: N/A
CIK: 1821323
Web: sigilon.com
Phone: N/A
Fax: N/A
Employees: 99
Year Founded: N/A

Sales & Book Value

Annual Sales: $13.37 million
Price / Sales: 5.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 32,309,000
Free Float: 28,787,000
Market Cap: $71.08 million
Optionable: Not Optionable

Company Calendar

Last Earnings: 11/10/2021
Today: 1/17/2022
Next Earnings (Estimated): 3/17/2022
Fiscal Year End: 12/31/2022

MarketRank^™

Overall MarketRank^™

1.94 out of 5 stars

Medical Sector

677th out of 1,417 stocks

3.2 Analyst's Opinion

Consensus Rating
Sigilon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.50, Sigilon Therapeutics has a forecasted upside of 240.9% from its current price of $2.20.
Amount of Analyst Coverage
Sigilon Therapeutics has only been the subject of 3 research reports in the past 90 days.

4.3 Community Rank

Outperform Votes
Sigilon Therapeutics has received 22 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Sigilon Therapeutics has received 12 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Sigilon Therapeutics has received 64.71% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Sigilon Therapeutics and other stocks. Vote “Outperform” if you believe SGTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Sigilon Therapeutics does not currently pay a dividend.
Dividend Growth
Sigilon Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sigilon Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.90% of the stock of Sigilon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
59.73% of the stock of Sigilon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Sigilon Therapeutics are expected to grow in the coming year, from ($2.29) to ($1.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sigilon Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sigilon Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Sigilon Therapeutics (NASDAQ:SGTX) Frequently Asked Questions

Is Sigilon Therapeutics a buy right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sigilon Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Sigilon Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGTX, but not buy additional shares or sell existing shares.
View analyst ratings for Sigilon Therapeutics or view top-rated stocks.
When is Sigilon Therapeutics' next earnings date?: Sigilon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Sigilon Therapeutics.
How were Sigilon Therapeutics' earnings last quarter?: Sigilon Therapeutics, Inc. (NASDAQ:SGTX) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.03. The company had revenue of $1.95 million for the quarter, compared to analyst estimates of $3.20 million.
View Sigilon Therapeutics' earnings history.
What price target have analysts set for SGTX?: 3 analysts have issued twelve-month target prices for Sigilon Therapeutics' shares. Their forecasts range from $4.00 to $14.00. On average, they anticipate Sigilon Therapeutics' stock price to reach $7.50 in the next year. This suggests a possible upside of 240.9% from the stock's current price.
View analysts' price targets for Sigilon Therapeutics or view top-rated stocks among Wall Street analysts.
Who are Sigilon Therapeutics' key executives?: Sigilon Therapeutics' management team includes the following people:
Dr. Rogerio Vivaldi Coelho M.D., MBA, Pres, CEO & Director (Age 57, Pay $802.37k)
Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 72, Pay $101.89k)
Dr. Daniel G. Anderson Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 51, Pay $100.63k)
Dr. Omid Veiseh Ph.D., Co-Founder
Dr. JosÃ© Oberholzer M.D., Co-Founder
Dr. Arturo Vegas Ph.D., Co-Founder
Mr. Philip Ashton-Rickardt Ph.D., Chief Scientific Officer
Mr. Robert Windsor Jr., J.D., VP & Head of Investor Relations
Mr. Matthew Kowalsky J.D., Chief Legal Officer (Age 49)
Ms. Vanya Sagar, Chief HR Officer (Age 46)
Who are some of Sigilon Therapeutics' key competitors?: Some companies that are related to Sigilon Therapeutics include Fusion Pharmaceuticals (FUSN), Akouos (AKUS), Intercure (INCR), MEI Pharma (MEIP), Progenity (PROG), Immutep (IMMP), MariMed (MRMD), Forian (FORA), ADMA Biologics (ADMA), Theratechnologies (THTX), Cardiff Oncology (CRDF), Compass Therapeutics (CMPX), Compass Therapeutics (CMPX), Entrada Therapeutics (TRDA) and Olema Pharmaceuticals (OLMA).
View all of SGTX's competitors.
When did Sigilon Therapeutics IPO?: (SGTX) raised $101 million in an initial public offering on Friday, December 4th 2020. The company issued 5,600,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity acted as the underwriters for the IPO.
What is Sigilon Therapeutics' stock symbol?: Sigilon Therapeutics trades on the NASDAQ under the ticker symbol "SGTX."
How do I buy shares of Sigilon Therapeutics?: Shares of SGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sigilon Therapeutics' stock price today?: One share of SGTX stock can currently be purchased for approximately $2.20.
How much money does Sigilon Therapeutics make?: Sigilon Therapeutics has a market capitalization of $71.08 million and generates $13.37 million in revenue each year.
How many employees does Sigilon Therapeutics have?: Sigilon Therapeutics employs 99 workers across the globe.
What is Sigilon Therapeutics' official website?: The official website for Sigilon Therapeutics is sigilon.com.

This page was last updated on 1/17/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Sigilon Therapeutics Stock Forecast, Price & News

About Sigilon Therapeutics

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Company Calendar

MarketRank™

Overall MarketRank™

3.2 Analyst's Opinion

4.3 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

1.7 Company Ownership

0.6 Earnings and Valuation

Sigilon Therapeutics (NASDAQ:SGTX) Frequently Asked Questions

Is Sigilon Therapeutics a buy right now?

When is Sigilon Therapeutics' next earnings date?

How were Sigilon Therapeutics' earnings last quarter?

What price target have analysts set for SGTX?

Who are Sigilon Therapeutics' key executives?

Who are some of Sigilon Therapeutics' key competitors?

When did Sigilon Therapeutics IPO?

What is Sigilon Therapeutics' stock symbol?

How do I buy shares of Sigilon Therapeutics?

What is Sigilon Therapeutics' stock price today?

How much money does Sigilon Therapeutics make?

How many employees does Sigilon Therapeutics have?

What is Sigilon Therapeutics' official website?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™